CURRENT TOPIC

Intravenous volume replacement: which fluid and why?

Lucinda Huskisson

Fluids available for intravenous volume replacement may be either crystalloid or colloid. The fundamental differences between these fluids are their effects on the Starling equation (table 1) which describes fluid flux between the intravascular and interstitial spaces. Starling stated that the rate of fluid movement into or out of a capillary is related to the net hydrostatic pressure minus the net colloid osmotic pressure. The Starling equation has been modified to include coefficients which represent the permeability of the capillary membrane to small solutes ($K_C$) and its ability to prevent large molecules such as plasma proteins from crossing it ($\alpha$). Colloids may be used to replenish the oncotic strength of the blood, thereby enhancing its water retaining capacity.

**Crystalloid versus colloid controversy**

Colloids are widely used in Europe for volume replacement, while crystalloids are the fluids of choice in many centres in the USA, but the relative merits of the two methods of management remain controversial.

Workers in favour of colloids insist that the intravascular colloid osmotic pressure must be kept either above the capillary hydrostatic pressure or at least greater than 10 mm Hg in critically ill patients to avoid a poor prognosis. Proponents of crystalloids maintain that colloids leak out of the capillaries, increasing interstitial colloid osmotic pressure which has a detrimental effect by increasing fluid flux out of the capillary. This is more likely to occur if $\alpha$ is reduced, as happens after burns, severe sepsis, and cardiopulmonary bypass.

Colloid solutions expand the intravascular space more effectively than crystalloids, with the same increase in cardiac output being achieved by smaller volumes and with less haemodilution. The crystalloid proponents argue that the interstitial space is depleted in conditions of hypovolaemia because of fluid shift into intravascular and intracellular compartments. The interstitial space fills more readily after crystalloid resuscitation. Because of this, the volume of fluid required is two to three times greater than when using colloids, resulting in an increased risk of tissue oedema. Sponsors of the crystalloid school maintain that this is not harmful despite the fact that tissue oedema has been associated with tissue hypoxia and has been implicated in delayed healing of bowel anastomoses. Despite the increased volumes required, crystalloid resuscitation is cheaper than the colloid equivalent (table 2).

Velanovich analysed the mortality data from a number of clinical trials and concluded that after trauma, or in instances when the capillaries are likely to have increased permeability, resuscitation is best achieved with crystalloids. In other circumstances—such as during major elective surgery—mortality rates may be reduced by using colloids.

The most appropriate resuscitation regimens undoubtedly involve the use of both crystalloids and colloids. Criteria for volume administration include tachycardia, hypotension, low filling pressures, reduced urine output, metabolic acidosis and increasing core-peripheral temperature gradient, although it should be remembered that a child can maintain a normal heart rate and systemic blood pressure despite a 25% loss of circulating volume. Volume administration should not be based on reflex prescribing—‘He looks volume depleted, therefore give 10 ml/kg of plasma’. An individual patient’s fluid requirements should be based on the aetiology of the volume depletion, and the most appropriate fluids should be used in adequate volumes.

### Intravenous fluids available

**CRYSTALLOIDS**

1. **Dextrose**

Because dextrose is rapidly metabolised after intravenous administration, 5% or 10% dextrose solutions act as free water, quickly equilibrating across cell membranes and are generally used in combination with another fluid.

<table>
<thead>
<tr>
<th>Fluid</th>
<th>Cost in £ per 500 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5% Albumin</td>
<td>33.00</td>
</tr>
<tr>
<td>20% Albumin</td>
<td>37.00</td>
</tr>
<tr>
<td>Hespan</td>
<td>16.72</td>
</tr>
<tr>
<td>Pentaspan</td>
<td>15.70</td>
</tr>
<tr>
<td>Gelofusine</td>
<td>3.56</td>
</tr>
<tr>
<td>Haemaccel</td>
<td>3.81</td>
</tr>
<tr>
<td>Rheomacrodex</td>
<td>6.51</td>
</tr>
<tr>
<td>Macrodex</td>
<td>4.11</td>
</tr>
<tr>
<td>Normal saline</td>
<td>0.78</td>
</tr>
<tr>
<td>Hartmann’s solution</td>
<td>0.88</td>
</tr>
</tbody>
</table>

**Table 1 Starling equation**

$$J = K_C [(P - P_t) - \alpha \sigma \tau]$$

Where

- $J$ = rate of fluid movement into/ out of capillary
- $K_C$ = capillary filtration coefficient
- $P$ = capillary hydrostatic pressure
- $P_t$ = tissue fluid hydrostatic pressure
- $\alpha$ = reflection coefficient
- $\sigma$ = capillary colloid osmotic pressure
- $\tau$ = tissue colloid osmotic pressure

**Table 2 Cost of volume replacement by various agents**
between the intracellular and extracellular fluid compartments. For every 100 ml infused, only 7.5 ml will remain in the intravascular space for a useful period of time, so dextrose solutions are inappropriate for intravascular fluid resuscitation.

(2) Isotonic crystalloid solutions
Isotonic crystalloids (for example, normal saline and Hartmann’s solution) equilibrate rapidly throughout both the interstitial and intravascular spaces, so approximately one quarter of the administered volume will remain within the intravascular space.

(3) Hypertonic saline solutions
These have shown a resurgence of popularity. Small volumes of 7.5% saline have successfully maintained the circulation after hypovolaemic shock. Their role in paediatrics has not yet been assessed, and hypertonic saline may prove inappropriate for neonates with immature sodium handling.

COLOID SOLUTIONS
Colloid solutions, both natural (for example, human albumin solutions) and the synthetic macromolecules (for example, the gelatins, hydroxyethyl starches, and dextrans), theoretically remain within the intravascular space. Thus, volume for volume, they provide a greater and more sustained haemodynamic response than crystalloids. In the UK, standard paediatric practice is to use natural colloids for resuscitation. Although synthetic colloids are used sporadically, there has been a reluctance to use them routinely because of a lack of clinical trials concerning their use in children.

BASIC STRUCTURE OF COLLOIDS
The chemical basis and source of the clinically important colloids are shown in table 3, and table 4 summarises the pharmacology. The two molecular weights quoted for synthetic colloids are defined in table 5. The weight average molecular weight \( M_w \) determines the viscosity, while the number average molecular weight \( M_n \) gives an indication of the osmotic pressure exerted by the fluid. Albumin is monodisperse—that is, all of the molecules within a solution are the same size and both \( M_w \) and \( M_n \) are 69 000. All of the synthetic colloids are polydisperse, and have different values for \( M_w \) and \( M_n \) (table 4).

PHARMACOLOGY OF INDIVIDUAL COLLOIDS

Natural colloids

(A) Fresh frozen plasma—fresh frozen plasma is extracted from donated blood and because it is unpasteurised it has the potential to transmit blood borne infections. The Consensus Conference held at the National Institutes of Health has laid down strict guidelines for the administration of fresh frozen plasma, concluding that there is no justification for its use as a volume expander.

(B) Albumin—Human albumin solution is derived from donated blood by fractionation and/or plasmapheresis. It is produced as a 4.5% solution (iso-oncotic with plasma) or as more concentrated (hyperoncotic) 10% or 20% solutions of ‘salt poor’ albumin.

Albumin persists within the body for about 20 days, although its duration of action within the intravascular compartment varies from less than two hours to more than a day.

Although freely donated, the processing of human albumin is expensive (table 2).

Synthetic colloids

(A) Gelatins—The gelatins tend to be considered as a homogeneous group but, because of different manufacturing processes, the individual solutions have differing properties, particularly in the incidence of adverse reactions. The new

---

### Table 3: Chemical basis and source of clinically important colloids

<table>
<thead>
<tr>
<th>Natural</th>
<th>Hydroxyethyl starches</th>
<th>Gelatins</th>
<th>Dextran</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source</td>
<td>Protein &amp; Blood</td>
<td>Carbohydrate &amp; Amylopectin</td>
<td>Protein &amp; Bovine collagen</td>
</tr>
<tr>
<td>Examples</td>
<td>Albumin FFP</td>
<td>Hesper &amp; Pentastarch</td>
<td>Gelofusine &amp; Haemaccel</td>
</tr>
<tr>
<td>Excretion</td>
<td>Liver/ kidneys</td>
<td>Pentastarch &amp; Amylase/RES</td>
<td>Kidneys</td>
</tr>
</tbody>
</table>

FFP, fresh frozen plasma; RES, reticuloendothelial system.

### Table 4: Characteristics of various colloids

<table>
<thead>
<tr>
<th></th>
<th>Albumin</th>
<th>Gelofusine</th>
<th>Haemaccel</th>
<th>Hetastarch</th>
<th>Pentastarch</th>
<th>Dextran 40</th>
<th>Dextran 70</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mw (kDa)</td>
<td>69</td>
<td>30</td>
<td>35</td>
<td>450</td>
<td>200</td>
<td>40</td>
<td>70</td>
</tr>
<tr>
<td>Mw (kDa)</td>
<td>69</td>
<td>22-5</td>
<td>24-5</td>
<td>71</td>
<td>35</td>
<td>25</td>
<td>39</td>
</tr>
<tr>
<td>Sodium (mM/l)</td>
<td>130-160</td>
<td>154</td>
<td>154</td>
<td>154</td>
<td>154</td>
<td>154</td>
<td>154</td>
</tr>
<tr>
<td>Potassium (mM/l)</td>
<td>1 &gt;0-4</td>
<td>5-1</td>
<td>&gt;0-4</td>
<td>12-5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Calcium (mM/l)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Duration of action (hours)</td>
<td>6-8</td>
<td>3-4</td>
<td>&gt;8</td>
<td>6-8</td>
<td>3-4</td>
<td>6-8</td>
<td></td>
</tr>
<tr>
<td>Survival in body (days)</td>
<td>2-65</td>
<td>7</td>
<td>7</td>
<td>6</td>
<td>28-42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water binding (ml H2O/g colloid)</td>
<td>18-21</td>
<td>42-8</td>
<td>41-7</td>
<td>20</td>
<td>30</td>
<td>37</td>
<td>29</td>
</tr>
</tbody>
</table>

---

### Table 5: Molecular weight definitions

- Weight average molecular weight \( M_w \) = sum of each molecule's weight
- Total mixture's weight × weight of the molecule
- Number average molecular weight \( M_n \) = mass of the sample in grams
- Total number of chains

After Hulse and Yacobi.™
Intravenous volume replacement: which fluid and why?

Intravenous volume replacement: which is used is Europe. Associated with capillary four discrepancies between albumin, with groups per endothelial derived from amylopectin fusine albumin, with groups per microgluen resulting the per resistance seen in the albumin. By diafiltering pentastarch, this product licence in the UK. It has five groups per 10 of glucose. Although it still contains a large range of molecular sizes, it does not include molecules with a weight greater than a million daltons. This gives the compound the advantage of a shorter persistence within the body, but with a similar efficacy to heterastarch.

By diafiltering pentastarch, all of the molecules with a $M_w$ of less than 100 000 daltons can be removed. This fluid (Pentafraction) is not commercially available, but preliminary animal work has suggested that its use may be associated with a reduction in capillary leak.

**Adverse Effects of Colloids**

1. **Anaphylactoid reactions**
   - These have been reported with both natural and synthetic colloids. The reactions may be mild/moderate or severe as classified by Ring and Messmer, and the precise causes of the reactions remain unclear. Release of histamine by the gelatins has been suggested: firstly, because the incidence is higher with urea linked rather than succinylated gelatins (0.1% and 0.05% respectively) and the former has been associated with free di-isocyanate, which causes histamine release; and secondly, the incidence of allergic reactions can be reduced by pre-treatment with H$_2$ and H$_3$ blockers.

The overall incidence of anaphylactoid reactions to HES is quoted at 0.08%, the majority of which are mild, although severe reactions have been reported. The dextran elicit the worst reactions, both in incidence and severity. These are mediated by dextran reactive antibodies which trigger the release of vasoactive mediators, and can be reduced by pretreatment with a hapten. The incidence of cardiac arrest associated with the dextran, together with their adverse effects on haemostasis and interference with the cross matching of blood are the main factors in their unpopularity.

2. **Coagulation effects**
   - Dilutional effects are seen with all the colloids (except fresh frozen plasma) but the polysaccharides have been associated with abnormalities of haemostasis which are more than simply dilutional. In particular, factor VIII concentrations may be appreciably reduced. Although in vitro may be altered by HES, the effects are rarely of clinical significance unless massive volumes are infused. The coagulation effects of the dextran are more pronounced, and the dextran are therefore used to reduce the incidence of postoperative venous thrombosis and fatal pulmonary embolism. As these complications are exceedingly rare in general paediatric surgery, they do not provide an indication for the use of dextran in infants and children, although dextran 40 is used in the postoperative period after orthotopic liver transplantation in an attempt to reduce thrombotic complications in the anastomosed vessels.

3. **Risks of infection**
   - The albumin solutions used in the UK are prepared from donated blood which is screened for antibodies to certain blood borne diseases. Because recently infected donors may carry a virus against which antibodies may not yet have been raised, the potential for infection (for example, with HIV or the hepatitis viruses) remains should the pasteurisation process fail.

4. **Interference with laboratory investigations**
   - The polysaccharides may interfere with cross matching reactions and estimations of the erythrocyte sedimentation rate by 'coating' the red cells and causing their aggregation. The effects of HES can be reversed by washing the cells with saline. The effects of dextran are long lasting, which is a major disadvantage in patients requiring blood after dextran administration.

The dextran have caused false positive glucose analysis results, and, together with Gelofusine, may interfere with the biuret determination of serum total protein. The gelatins...
migrate within the \(\alpha\)-fraction in electrophoresis, but do not appear to affect immunological assays.\(^{42}\)

Amylase contributes to the elimination of HES from the body, and the serum amylase value may double after HES infusion.\(^{44}\)

**CLINICAL STUDIES WITH SYNTHETIC COLLOIDS**

There is a wealth of literature describing the adult experience with synthetic colloids, and a corresponding paucity of paediatric studies.

Boon has published his experience with Haemaccel over 14 years in more than 8000 patients,\(^{45}\) whilst Lundsgaard-Hansen and Tschirren\(^{46}\) have reported 20 years experience with Gelofusine. Both papers conclude that these two fluids are safe, effective, and worthwhile fluids for volume replacement. In critically ill patients, Gelofusine has been associated with increased oxygen consumption.\(^{47}\)

Six per cent HES was equal to albumin for peroperative volume replacement during paediatric anaesthesia.\(^{48}\) HES has been used satisfactorily in the pump prime for bloodless open heart surgery in children who are Jehovah’s Witnesses.\(^{49}\) It has been studied extensively in adults with the conclusion that there is no difference between HES and albumin, with HES offering a considerable cost saving.\(^{50-52}\)

Despite their unacceptable level of adverse effects, there is little doubt that the dextranss are very efficient plasma expanders.\(^{33}53-55\)

**PRESCRIBING PITFALLS**

(1) Serum albumin and measurement of colloid osmotic pressure

Under normal conditions, only half of the body’s endogenous albumin is intravascular, but it contributes about 80% of the intravascular colloid osmotic pressure.\(^{56}\) In critically ill patients, because of the ‘acute phase reaction’, the serum albumin concentrations may not provide an accurate reflection of the colloid osmotic pressure as the production of acute phase proteins takes precedence over the synthesis of albumin. Albumin may be administered not because volume replacement is required, but because the serum albumin concentration is low.

(2) Inadequate resuscitation

Problems with crystalloid resuscitation are often related to inadequate volumes being administered, because the prescriber fails to allow for fluid movement into the interstitial compartment.

(3) Volume overload

While the gelatins are plasma substitutes, and can be used interchangeably with albumin, the dextrans and hydroxyethyl starches are true plasma expanders—that is, they produce an increase in plasma volume greater than the volume of colloid infused. Although this may be of clinical benefit, the risk of fluid overload and significant haemodilution is greater when administered by unwary prescribers.

**Conclusions**

Although there are certain indications for natural colloids—for example, after certain open heart operations when massive colloid infusion may be required, synthetic colloids could often be given in their place. Because of their safety, the gelatins (particularly the modified fluid gelatins) are the most appropriate choice but there are situations when the superior plasma expansion of hydroxyethyl starches may be required. Although studies with synthetic colloids in adult patients may be extrapolated to the paediatric population, there remains a need for an evaluation of synthetic colloids in paediatric practice.


Downloaded from http://adc.bmj.com/ on October 29, 2017 - Published by group.bmj.com
Intravenous replacement: which fluid and why?

48 Hausdorfer J, Hagemann H, Heine J. Comparison of plasma substitutes human albumin 5% and hydroxyethyl starch 6% (40,000, 0.5) in paediatric anaesthesia. Anaesth Intensivether Notfmedizin 1986;21:137–42.
Intravenous volume replacement: which fluid and why?

L Huskisson

Arch Dis Child 1992 67: 649-653
doi: 10.1136/adc.67.5.649

Updated information and services can be found at:
http://adc.bmj.com/content/67/5/649.citation

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/